share_log

新興市場銘柄ダイジェスト:ステムリムは急騰、アスカネットがストップ高

Emerging markets stock digest: Daijessutsu: STEM inc. has surged, Asukanetto has hit the price ceiling.

Fisco Japan ·  Jul 9 15:10

<9337> Toridori 1761 -38 <4427> EduLab 358 +80 <2438> Asukanet 700 +100 Trading Limit Up. In the Nikkan Kogyo Shimbun on the 9th, it was reported that the company aims to adopt its proprietary air display technology that projects images in the air through an optical plate on overseas mass-produced cars in FY2024, which is considered good news. It is expected to be used in car displays and infotainment systems for electric vehicles (EVs) from emerging China-based manufacturers.

After falling for 3 consecutive days, the stock rose following the announcement of the joint venture agreement to establish a joint venture company to develop SKD Promotion and influencer marketing business after the close of trading on the 5th but then fell again. Combining the advertising network and influencer network of the company with the elaborate influencer operation of SKD, it aims to strengthen the influencer development organization, work on building the next-generation influencer network, and further expand the performance-based advertising service area.

<9337> Toridori 1761 -38 <4427> EduLab 358 +80 <2438> Asukanet 700 +100

Stock price limit up. On the 8th, the Ministry of Education, Culture, Sports, Science and Technology showed a plan to completely switch to a new method (CBT) of using computer terminals to question and answer online, abandoning paper problem booklets for the National Learning Ability Test targeting all sixth graders and third graders in junior high school, from the fiscal year 27, which has caused the stock price of the company that has received the order to increase.

Please use your Futubull account to access the feature.

Stop trading limit up. In the Nikkan Kogyo Shimbun on the 9th, it was reported that the company aims to adopt its proprietary air display technology that projects images in the air through an optical plate on overseas mass-produced cars in FY2024, which is considered good news. It is expected to be used in car displays and infotainment systems for electric vehicles (EVs) from emerging China-based manufacturers.

<9558> Japaniasu 2163 -157

Year-to-date low update. Selling is leading due to the fact that operating profit for the second quarter of the 24th fiscal year accumulated to date was 310 million yen, a decrease of 25.2% compared to the same period of the previous year. It is thought that the increase in sales costs, selling expenses and general administrative expenses due to the active employment of engineers and the decrease in gross profit margin due to an increase in training targets, including new graduates, are the reasons. On the other hand, it has also announced that it will implement an interim dividend from the 24th November period and a share buyback of up to 0.06 million shares (100 million yen in value) which is equivalent to 1.5% of issued shares (excluding treasury shares).

<9238> ValueC 1275 +179

Temporary stop high. It has been well received by announcing the expansion of the shareholder benefit system after the close of trading on the 5th. The previous gift award for holders of 100 or more shares on the last day of February each year has been increased from 500-2,000 yen to 1,500-6,000 yen according to the number of shares held and the duration of ownership. In addition, the content of the first anniversary shareholder benefit has been changed, and shareholders who own 100 or more shares as of the end of August 24 will receive a QUO card worth 3,000 yen (compared to 1,000 yen in the past), regardless of the duration of ownership.

<4599> Stemlim 460 +39

Sharp rise. After the close of trading on the 8th, it was announced that a patent for the use of PJ5: gene therapy for nutritional disorder-type epidermolysis bullosa, which is being jointly studied with the joint research course of the Institute of Medical Science, Graduate School of Medicine, Osaka University, would be registered in Japan, which was well received. The patent is intended to protect the gene therapy technology for the radical treatment of nutritional disorder-type epidermolysis bullosa, making it possible to secure the exclusivity of business in Japan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment